For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
The Weill Cornell Medicine (WCM) SPORE consists of four Projects focused on highly translational areas relevant to the detection and treatment of aggressive prostate cancer (PCa).
Projects 1, 2, and 4 build on first-in-class discoveries made by study co-leaders that are fostered with significant preliminary data. Project 3 builds on highly collaborative interactions with multiple SPORE groups, using state-of-the-art genomics in a Clinical Laboratory Improvement Amendments (CLIA) setting.
PROJECTS: Project 1, Project 2, Project 3, Project 4
- Develop accurate biomarkers to assess the risk of PCa disease progression
- Develop new therapeutic approaches for clinically localized and CRPC that are hypothesis-driven
- Leverage existing and expand new infrastructure for the successful translation of pre-clinical studies into the clinic
- Train the next generation of PCa investigators through the CEP and DRP
